Is Eupraxia Pharmaceuticals Inc. (EPRX.TO) a Buy, Sell, or Hold?
TSX : EPRX.TO
Eupraxia Pharmaceuticals Inc.
$9.2 CAD
$0.21 (2.34%)
- Volume
- 69.39K
- Average Volume
- 63.22K
- Market Capitalization
- $330.63M
- P/E Ratio
- -6.22
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $12.86
- Year Low
- $6.87
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $19.30
Company Overview
TSX
James A. Helliwell
Biotechnology
Healthcare
EPRX.TO
49
CA
CAD
Liquidity Metrics
0.01
19.30
19.30
7.95
0.00
Sales & Valuation
-$
0.00
2.69
-7.30
-0.57
Profitability
-$1.05
-$39.25M
0.00%
0.00%
-53.61%
-30.60%
P/E Metrics
-6.22
0.16
0.16
Analyst Price Target & Rating
2/5
2 Analysts
%
Financial Health Scores
19.10
2/9
$134.86M
$145.46M
$9.17M
-$44.89M
Key Metrics (TTM)
No key metrics data available.
Company Executives
| Name | Title |
|---|---|
| Amanda Malone | Chief Scientific Officer & Chief Operating Officer |
| Alex Therien | Executive VP of R&D |
| James A. Helliwell FRCPC | Chief Executive Officer & Director |
| Alexander John Rothwell | Chief Financial Officer |
| Paul Anthony Brennan | Chief Corporate Development Officer |
| Wajida Leclerc CHRP | Executive Vice President Corporate Services & People |
| Jeymi Tambiah | Chief Medical Officer |
Poll Results
No votes yet today — be the first to share your view!
About Eupraxia Pharmaceuticals Inc. (TSX:EPRX.TO) Stock
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, targeting both critical unmet medical needs and pain management for knee osteoarthritis. This promising candidate is also being developed for veterinary use, specifically for canine and equine osteoarthritis. Eupraxia's broader development portfolio includes EP-201, an antibiotic aimed at preventing post-surgical site infections, and EP-105, an extended-release anesthetic designed for extended post-operative pain relief. Furthermore, the company is actively developing product candidates for oncology applications. Established in 2011 and headquartered ... in Victoria, Canada, Eupraxia Pharmaceuticals Inc. was formerly known as Plaza Capital Partners Inc. until its renaming in May 2012.
Frequently Asked Questions
-
What is the current Eupraxia Pharmaceuticals Inc. (EPRX.TO) stock price?
-
Eupraxia Pharmaceuticals Inc.(TSX:EPRX.TO) stock price is $9.2 in the last trading session. During the trading session, EPRX.TO stock reached the peak price of $12.86 while $6.87 was the lowest point it dropped to. The percentage change in EPRX.TO stock occurred in the recent session was 2.34% while the dollar amount for the price change in EPRX.TO stock was $0.21.
-
EPRX.TO's industry and sector of operation?
-
The TSX listed EPRX.TO is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of EPRX.TO?
-
Amanda Malone | Chief Scientific Officer & Chief Operating Officer
Alex Therien | Executive VP of R&D
James A. Helliwell FRCPC | Chief Executive Officer & Director
Alexander John Rothwell | Chief Financial Officer
Paul Anthony Brennan | Chief Corporate Development Officer -
How many employees does EPRX.TO have?
-
Number of EPRX.TO employees currently stands at 49. EPRX.TO operates from 2067 Cadboro Bay Road, Victoria, BC V8R 5G4, CA.
-
Link for EPRX.TO official website?
-
Official Website of EPRX.TO is: https://www.eupraxiapharma.com
-
How do I contact EPRX.TO?
-
EPRX.TO could be contacted at phone #250-590-3968 and can also be accessed through its website. EPRX.TO operates from 2067 Cadboro Bay Road, Victoria, BC V8R 5G4, CA.
-
How many shares of EPRX.TO are traded daily?
-
The average number of EPRX.TO shares traded daily for last 3 months was 63.22K.
-
What is the market cap of EPRX.TO currently?
-
The market value of EPRX.TO currently stands at $330.63M with its latest stock price at $9.2